SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response
FEBS Open Bio · 2024
DOI: 10.1002/2211-5463.13899 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2024. Verfasst von Yuming Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Nuclear Proteins, Transcription Factors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project.
Abstract (Originalsprache)
The switch/sucrose non‐fermenting (SWI/SNF) complex family includes important chromatin‐remodeling factors that are frequently mutated in lung adenocarcinoma (LUAD). However, the role of one family member, SMARCA4 , in LUAD prognosis and immunotherapy sensitivity remains unclear. In the present study, 6745 LUAD samples from the cBioPortal database were used to analyze the relationships between SMARCA4 mutations and patient prognoses and clinical characteristics. Additionally, we examined the correlation between SMARCA4 mutations and prognosis in patients treated with immunotherapy using two immune‐related datasets. SMARCA4 mutations and low expression were associated with shorter survival, and mutations were associated with a high tumor mutational burden and high microsatellite instability. SMARCA4 mutations were accompanied by KRAS , KEAP1 , TP53 and STK11 mutations. No significant difference was observed in the immunotherapy response between patients with and without SMARCA4 mutations. When KRAS or STK11 mutations were present, immunotherapy effectiveness was poorer; however, when both SMARCA4 and TP53 mutations were present, immunotherapy was more effective. Furthermore, low SMARCA4 expression predicted a higher immunophenoscore, and SMARCA4 expression was correlated with certain immune microenvironment features. Taken together, our results suggest that SMARCA4 mutations and low expression might be associated with poor LUAD prognosis. Additionally, immunotherapy efficacy in patients with SMARCA4 mutations depended on the co‐mutant genes. Thus, SMARCA4 could be an important factor to be considered for LUAD diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, China.
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao University, China.
- Department of Oncology, Qingdao Municipal Hospital, China.
- Department of Thoracic Surgery, The Affiliation Hospital of Qingdao University, China.
ORCID-Profile: Yuming Zhang
Förderung
- Natural Science Foundation of Shandong Province
- Special Funding for Qilu Sanitation and Health Leading Talents Cultivation Project
Zitieren
APA
Zhang, Y., Sun, D., Han, W., Yang, Z., Lu, Y., Zhang, X., Wang, Y., Zhang, C., Liu, N., & Hou, H. (2024). SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13899
Vancouver
Zhang Y, Sun D, Han W, Yang Z, Lu Y, Zhang X, et al. SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response. FEBS Open Bio. 2024. doi:10.1002/2211-5463.13899
BibTeX
@article{Zhang2024,
author = {Zhang, Yuming and Sun, Dantong and Han, Weizhong and Yang, Zhen and Lu, Yongzhi and Zhang, Xuchen and Wang, Yongjie and Zhang, Chuantao and Liu, Ning and Hou, Helei},
title = {SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response},
journal = {FEBS Open Bio},
year = {2024},
doi = {10.1002/2211-5463.13899}
}
EUVIMED